Biotechnology business in Norway: Peripheral advantage, or just periphery?
AbstractResearch on biotechnology related firms has long been associated with the agglomeration of “dedicated biotechnology firms” and partners such as large corporations, research institutes and venture capital firms. At the same time it is acknowledged that such agglomeration trends may be most closely associated with medical biotechnology. This paper shows that there are more than 130 firms which may be classified as biotechnology related firms in Norway. Furthermore they are spread out throughout the country, albeit with more than half being located in the Eastern part. While there is indeed a great preoccupation with medical biotechnology also in Norway, the survey shows that two other distinct traits are present: a concentration of firms being focused on diagnostics and drug delivery rather than on therapeutics, and a focus on marine biotechnology (more than one third of the firms) within nutrition related products rather than or in addition to medical products. In addition to contributing these descriptive findings the paper thus opens up the agglomeration discussion, and suggests that foci on such niches as those which are prevalent in Norway may function with geographical distribution patterns different from those prevalent within the current medical biotechnology focused literature.
Download InfoIf you experience problems downloading a file, check if you have the proper application to view it first. In case of further problems read the IDEAS help page. Note that these files are not on the IDEAS site. Please be patient as the files may be large.
Bibliographic InfoPaper provided by Centre for Technology, Innovation and Culture, University of Oslo in its series Working Papers on Innovation Studies with number 20070607.
Length: 42 pages
Date of creation: Aug 2007
Date of revision:
This paper has been announced in the following NEP Reports:
- NEP-ALL-2007-08-14 (All new papers)
Please report citation or reference errors to , or , if you are the registered author of the cited work, log in to your RePEc Author Service profile, click on "citations" and make appropriate adjustments.:
- Günseli Baygan, 2003. "Venture Capital Policy Review: Norway," OECD Science, Technology and Industry Working Papers 2003/17, OECD Publishing.
- Gunnar Eliasson, 2000. "Industrial policy, competence blocs and the role of science in economic development," Journal of Evolutionary Economics, Springer, vol. 10(1), pages 217-241.
- Susan Bartholomew, 1997. "National Systems of Biotechnology Innovation: Complex Interdependence in the Global System," Journal of International Business Studies, Palgrave Macmillan, vol. 28(2), pages 241-266, June.
- Niosi, Jorge, 2003. "Alliances are not enough explaining rapid growth in biotechnology firms," Research Policy, Elsevier, vol. 32(5), pages 737-750, May.
- Goldfarb, Brent & Henrekson, Magnus & Rosenberg, Nathan, 2001. "Demand vs. Supply Driven Innovations: US and Swedish Experiences in Academic Entrepreneurship," Working Paper Series in Economics and Finance 0436, Stockholm School of Economics.
For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: (H&kon Normann).
If references are entirely missing, you can add them using this form.